Skip to main content
Elsevier

Progress in Molecular Biology and Translational Science

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A

  • 1st Edition, Volume 162 - March 22, 2019
  • Latest edition
  • Editor: Lijuan Zhang
  • Language: English

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A, Volume 162 in the Progress in Molecular Biology and Translational Science series provides informati… Read more

Data Mining & ML

Unlock the cutting edge

Up to 20% on trusted resources. Build expertise with data mining, ML methods.

Explore now

Description

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A, Volume 162 in the Progress in Molecular Biology and Translational Science series provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include Glycan-based Biomarkers for Diagnosis of Cancers and Other Diseases: Past, Present and Future, Desialylation in Diseases and its Application in Diagnostic and Therapeutic Development, Proteoglycans as Miscommunication Biomarkers for Cancer Diagnosis, Fucosylation in Cancer Biology and Its Clinical Applications, Retrospective Analysis of Glycan-Related Biomarkers Based on Clinical Laboratory Data in Two Medical Centers, and many related topics.

Key features

  • Includes comprehensive coverage of molecular biology
  • Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
  • Contains contributions from renowned experts in the field

Readership

Scientists working actively in the field, including those at levels ranging from graduate student to senior investigator. Volumes also are appropriate for new investigators to a field who wish to familiarize themselves with the latest work

Table of contents

1. Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future
Minghui Hu, Ying Lan, Alexander Lu, Xuexiao Ma and Lijuan Zhang

2. Desialylation in physiological and pathological processes: New target for diagnostic and therapeutic development
Mohui Wei and Peng George Wang

3. Proteoglycans as miscommunication biomarkers for cancer diagnosis
Lingling Xu, Limin Tang and Lijuan Zhang

4. Fucosylation in cancer biology and its clinical applications
Ming Shan, Dandan Yang, Huaiqian Dou and Lijuan Zhang

5. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection
Yang Tang, Yidi Cui, Shufeng Zhang and Lijuan Zhang

6. Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past six years
Meng Zhang, Huaiqian Dou, Dandan Yang, Ming Shan, Xiulian Li, Cui Hao, Yiran Zhang, Pengjiao Zeng, Yanli He, Yong Liu, Jing Fu, Wei Wang, Minghui Hu, Hui Li, Qingwu Tian, Shuhe Lei and Lijuan Zhang

7. Serum SCCA levels in patients suffering cancers or other diseases
Dandan Yang, Jun Wang and Lijuan Zhang

8. Increased serum CA724 levels in patients suffering gout vs cancers
Yiran Zhang, Meng Zhang, Xueshan Bai, Changgui Li and Lijuan Zhang

9. Serum CA50 levels in patients with cancers and other diseases
Ming Shan, Qingwu Tian and Lijuan Zhang

10. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases
Yanli He, Haijun Lu and Lijuan Zhang

11. Serum CEA levels in 49 different types of cancer and noncancer diseases
Cui Hao, Guoqing Zhang and Lijuan Zhang

12. CA242 as a biomarker for pancreatic cancer and other diseases
Huaiqian Dou, Guirong Sun, and Lijuan Zhang

13. Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers
Meng Zhang, Yiran Zhang, Jing Fu and Lijuan Zhang

14. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases
Pengjiao Zeng, Hui Li, Yulong Chen, Haitao Pei and Lijuan Zhang

15. Serum CA153 as biomarker for cancer and non-cancer diseases
Xiulian Li, Yan Xu and Lijuan Zhang

16. Fasting blood glucose levels in patients with different types of diseases
Qinghua Zhang, Gang Zhao, Nailong Yang and Lijuan Zhang

17. HbA1c: High in acute cerebral infarction and low in brain trauma
Zhifeng Jiang, Jigang Wang, Peng Zhao, Lijuan Zhang and Yunliang Guo

18. Glycated albumin level is significantly decreased in patients suffering nephrotic syndrome
Zhe Wang, Guangqun Xing, Lijuan Zhang

19. Glycated serum proteins: High in pancreatic cancer and low in preeclampsia
Xueling Wang, Rui Zhang, Lijuan Zhang and Zibin Tian

20. The serum SA levels are significantly increased in sepsis but decreased in cirrhosis
Xiaodan Huang, Qin Yao, Lijuan Zhang and Zibin Tian

21. Serum α-L-fucosidase activities are significantly increased in patients with preeclampsia
Meng Zhang, Lin Wang, Haiping Zhang, Juan Cong and Lijuan Zhang

22. Glucuronidated bilirubin: Significantly increased in hepatic encephalopathy
Limin Tang, Meng Zhang, Xiulian Li and Lijuan Zhang

23. Serum PSA levels in patients with prostate cancer and other 33 different types of diseases
Yanyun Gao, Meng Zhang, Xiulian Li, Pengjiao Zeng, Peitao Wang and Lijuan Zhang

Product details

  • Edition: 1
  • Latest edition
  • Volume: 162
  • Published: March 22, 2019
  • Language: English

About the editor

LZ

Lijuan Zhang

Lijuan Zhang is a Professor of Translational Medicine at Ocean University of China. She completed her doctorates of biochemistry and molecular genetics at University of Alabama at Birmingham in 1995. Before then, she was a Fogarty International Fellow at NIH for three years studying glycan-based cancer biomarkers. She worked as post-doctorate fellow and research associate at both MIT and Harvard Medical School from 1995-2002. She joined the faculty of the Department of Pathology & Immunology at Washington University in St. Louis in 2002 as a tenure-tracked Assistant Professor. Her research had been focused on the biosynthesis, structures, and biological functions of glycans since 1985. Now her work is on translational aspects of glycans as biomarkers and therapeutics. She has over 60 peer reviewed publications. She edited and published a book entitled “Glycosaminoglycans in Development, Health, and Diseases” with the contributions of top scientists worldwide in 2010 by Elsevier.
Affiliations and expertise
Ocean University of China, Qingdao, China

View book on ScienceDirect

Read Progress in Molecular Biology and Translational Science on ScienceDirect